Read on Twitter
“TRV130 prevented acute brain hypoxia induced by moderate doses of oxycodone.”
TRV130 is $TRVN Trevena’s lead candidate (Oliceridine) that is an IV-delivered medication for moderate-to-severe pain, and has an 8/7 PDUFA date.
https://pubmed.ncbi.nlm.nih.gov/32305216/
TRV130 is $TRVN Trevena’s lead candidate (Oliceridine) that is an IV-delivered medication for moderate-to-severe pain, and has an 8/7 PDUFA date.
https://pubmed.ncbi.nlm.nih.gov/32305216/
This data from the animal study, in addition to the @US_FDA ‘s own conclusions from the 2018 Advisory Committee meeting, both speak VOLUMES to the safety of this drug.
https://www.fda.gov/media/121231/download
https://www.fda.gov/media/121231/download
Safety has also been validated in the ‘type A’ meeting that $TRVN had with the FDA in 01/2019. https://www.trevena.com/investors/press-releases/detail/160/trevena-announces-receipt-of-type-a-meeting-minutes-and
Furthermore, since $TRVN pipeline candidate TRV734 is essentially the oral analog of TRV130, it seems like TRV734 (in phase II, funded by NIDA) could help prevent brain injury associated with opioid overdose and opioid use disorder.
$TRVN Thats a pipeline that has proven safety and efficacy for both moderate-to-severe pain and opioid use disorder/maintenance therapy....and thats not even mentioning TRV027, their #COVID19 therapeutic currently being tested by @imperialcollege https://www.sciencefocus.com/news/coronavirus-blood-trial-targets-hormone-imbalance/
Really hope @NIH is paying attention to this drug platform that could be a huge value-add in both the fights against the coronavirus pandemic and opioid epidemic
